ReviewNanomedicine (London, England)2025
LPS-focused nanomedicine for potent antibacterial therapy.
Review in Nanomedicine (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
A significant upsurge in antibiotic-resistant infections, mainly due to the Gram-negative bacteria (GNB), is a major global concern. These GNBs carry lipopolysaccharides (LPS), a complex outer membrane component that endows them with structural integrity and acts as a formidable barrier against most antibiotics. Targeting LPS has thus emerged as a promising frontier in antibacterial nanomedicine. This review explores the structure of LPS and its pivotal role in bacterial virulence and immune evasion. We have highlighted diverse nanoparticle-based strategies like antibodies, peptides, aptamers, and small molecules that selectively bind and neutralize the LPS. Additionally, we have tried to present the key mechanisms of action of these NPs, which include membrane disruption, neutralization of the endotoxin, etc. Overall, this review provides a clear picture of how LPS-targeting NPs could aid in combating drug-resistant and deadly infections in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.